Rezolute, Inc. Common Stock (NV)
RZLT
RZLT: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
moreShow RZLT Financials
Recent trades of RZLT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RZLT's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Crystalline forms of plasma kallikrein inhibitors Apr. 19, 2022
-
Patent Title: Processes for preparing plasma kallikrein inhibitors Mar. 08, 2022
-
Patent Title: Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates Jul. 07, 2020
-
Patent Title: Coiled tube emulsification systems Feb. 18, 2020
-
Patent Title: Amine pegylation methods for the preparation of site-specific protein conjugates Mar. 05, 2019
-
Patent Title: Solvent extraction from biodegradable microparticles Nov. 27, 2018
-
Patent Title: Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates Aug. 14, 2018
Federal grants, loans, and purchases
Followers on RZLT's company Twitter account
Number of mentions of RZLT in WallStreetBets Daily Discussion
Recent insights relating to RZLT
Recent picks made for RZLT stock on CNBC
ETFs with the largest estimated holdings in RZLT
Flights by private jets registered to RZLT